Kombe Mwitwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kombe Mwitwa has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Bolaji Samuel Mesole
Human Anatomy Unit Department of Medicine and Clinical Sciences , Eden University, Lusaka, Zambia, Zambia
3 shared publications - Jonathan Chinyama
Department of Medicine and Clinical Sciences, Eden University, Lusaka, Zambia, Zambia
3 shared publications - Alfred Omachonu Okpanachi
Department of Physiology, Faculty of Biomedical Sciences, Kampala International University, Western Campus, Box 71, Bushenyi, Uganda
2 shared publications - Sharon Kaundu2 shared publications
- Uthman Ademola Yusuf
Department of Human Anatomy, School of Medicine and Health Sciences, Mulungushi University, Livingstone Campus, Zambia
2 shared publications - Alfred Omachonu Okpanachi
Department of Medicine and Clinical Sciences, Eden University, Lusaka, Zambia, Zambia
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Preprints.org
HPA-Axis Dysregulation in Metal and Metalloid-Associated Neurotoxicity: Distinguishing Causal Mediation, Stress Interactions and Secondary Responses
Environmental metal and metalloid exposure are associated with altered hypothalamic–pituitary–adrenal (HPA) axis activity and neurological dysfunction, but the causal role of neuroendocrine changes remains uncertain. This critical review evaluates four competing explanations: HPA-axis dysregulation mediates neural injury; independent stress modifies toxicant effects; endocrine and neuronal disturbances arise through parallel mechanisms; or endocrine changes follow neural or systemic injury. We critically appraise evidence linking glucocorticoid dynamics, glucocorticoid/mineralocorticoid receptor signalling, inflammation and neural dysfunction, emphasising temporality, endocrine sampling, intervention specificity, internal toxicant burden and confounding. Selected experimental studies support glucocorticoid receptor (GR) involvement in particular neural outcomes, but general mediation of metal-associated neurotoxicity by systemic HPA-axis dysfunction remains unestablished. Likewise, greater injury under combined toxicant and stress exposure does not by itself demonstrate biological synergy or endocrine mediation. We distinguish associative findings from temporal support, experimentally tested pathway dependence and convergent functional evidence, while considering alternative mechanisms, including altered toxicant disposition. Priority studies should integrate longitudinal endocrine phenotyping, exposure-relevant factorial designs, receptor-selective interventions, tissue toxicant quantification and neurological outcomes. These approaches could distinguish causal neuroendocrine mechanisms from parallel or secondary responses and improve the interpretation of metal-associated neurological injury.
- 6 November 2026
- Published by MDPI AG in Preprints.org
Open AccessHPA-Axis Dysregulation in Metal and Metalloid-Associated Neurotoxicity: Distinguishing Causal Mediation, Stress Interactions and Secondary Responses
Environmental metal and metalloid exposure are associated with altered hypothalamic–pituitary–adrenal (HPA) axis activity and neurological dysfunction, but the causal role of neuroendocrine changes remains uncertain. This critical review evaluates four competing explanations: HPA-axis dysregulation mediates neural injury; independent stress modifies toxicant effects; endocrine and neuronal disturbances arise through parallel mechanisms; or endocrine changes follow neural or systemic injury. We critically appraise evidence linking glucocorticoid dynamics, glucocorticoid/mineralocorticoid receptor signalling, inflammation and neural dysfunction, emphasising temporality, endocrine sampling, intervention specificity, internal toxicant burden and confounding. Selected experimental studies support glucocorticoid receptor (GR) involvement in particular neural outcomes, but general mediation of metal-associated neurotoxicity by systemic HPA-axis dysfunction remains unestablished. Likewise, greater injury under combined toxicant and stress exposure does not by itself demonstrate biological synergy or endocrine mediation. We distinguish associative findings from temporal support, experimentally tested pathway dependence and convergent functional evidence, while considering alternative mechanisms, including altered toxicant disposition. Priority studies should integrate longitudinal endocrine phenotyping, exposure-relevant factorial designs, receptor-selective interventions, tissue toxicant quantification and neurological outcomes. These approaches could distinguish causal neuroendocrine mechanisms from parallel or secondary responses and improve the interpretation of metal-associated neurological injury.
- Open Access
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Dimethyl fumarate attenuates cadmium-induced oxidative injury and apoptosis-associated signalling in the rat hippocampus and prefrontal cortex
Cadmium neurotoxicity is associated with oxidative injury, impaired antioxidant defence and dysregulated apoptosis-associated signalling. This study investigated whether dimethyl fumarate (DMF) attenuates cadmium chloride (CdCl₂)-induced biochemical injury in the hippocampus and prefrontal cortex of male Wistar rats. Thirty-two rats were randomly allocated to Control, CdCl₂ (5 mg/kg/day), DMF (25 mg/kg/day) and CdCl₂+DMF groups (n = 8/group) and treated orally for 30 days. Malondialdehyde (MDA), total nitrate/nitrite (NOx), 8-hydroxy-2′-deoxyguanosine (8-OHdG), superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), reduced glutathione (GSH), PUMA, caspase-3, BAX and BCL-2 were assessed in both regions. CdCl₂ increased MDA, NOx, 8-OHdG, PUMA, caspase-3 and BAX, reduced SOD, catalase, GPx, GSH and BCL-2, and markedly increased the BAX/BCL-2 ratio. DMF co-treatment significantly attenuated these alterations. Hippocampal PUMA increased from 1.00 ± 0.18 to 2.48 ± 0.42-fold of Control and was reduced to 1.39 ± 0.25 by DMF, while the BAX/BCL-2 ratio fell from 5.76 ± 1.36 to 1.86 ± 0.45. Comparable protection occurred in the prefrontal cortex. These findings support DMF-mediated biochemical neuroprotection associated with restored antioxidant defence and attenuation of PUMA/BCL-2-family-associated pro-apoptotic signalling, although recovery of selected oxidative and hippocampal apoptosis-associated endpoints remained incomplete overall.
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDimethyl fumarate attenuates cadmium-induced oxidative injury and apoptosis-associated signalling in the rat hippocampus and prefrontal cortex
Cadmium neurotoxicity is associated with oxidative injury, impaired antioxidant defence and dysregulated apoptosis-associated signalling. This study investigated whether dimethyl fumarate (DMF) attenuates cadmium chloride (CdCl₂)-induced biochemical injury in the hippocampus and prefrontal cortex of male Wistar rats. Thirty-two rats were randomly allocated to Control, CdCl₂ (5 mg/kg/day), DMF (25 mg/kg/day) and CdCl₂+DMF groups (n = 8/group) and treated orally for 30 days. Malondialdehyde (MDA), total nitrate/nitrite (NOx), 8-hydroxy-2′-deoxyguanosine (8-OHdG), superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), reduced glutathione (GSH), PUMA, caspase-3, BAX and BCL-2 were assessed in both regions. CdCl₂ increased MDA, NOx, 8-OHdG, PUMA, caspase-3 and BAX, reduced SOD, catalase, GPx, GSH and BCL-2, and markedly increased the BAX/BCL-2 ratio. DMF co-treatment significantly attenuated these alterations. Hippocampal PUMA increased from 1.00 ± 0.18 to 2.48 ± 0.42-fold of Control and was reduced to 1.39 ± 0.25 by DMF, while the BAX/BCL-2 ratio fell from 5.76 ± 1.36 to 1.86 ± 0.45. Comparable protection occurred in the prefrontal cortex. These findings support DMF-mediated biochemical neuroprotection associated with restored antioxidant defence and attenuation of PUMA/BCL-2-family-associated pro-apoptotic signalling, although recovery of selected oxidative and hippocampal apoptosis-associated endpoints remained incomplete overall.
- Open Access
- 15 August 2026
- Published by Elsevier in SSRN Electronic Journal
ML385 inhibition of NRF2 partially attenuates dimethyl fumarate-mediated redox and mitochondrial protection in cadmium neurotoxicity
Cadmium disrupts neuronal redox control and mitochondrial energy production, but whether dimethyl fumarate (DMF) protects the brain mainly through NRF2 remains uncertain. Adult male Wistar rats were assigned to control, cadmium, DMF, ML385, cadmium plus DMF, cadmium plus ML385, or cadmium plus DMF plus ML385 groups (n = 12/group). Cadmium chloride (5 mg/kg) and DMF (25 mg/kg) were administered orally, while ML385 (30 mg/kg) was given intraperitoneally, daily for 30 days. Brain cadmium, NRF2 binding to antioxidant response elements in the Nqo1 and Gclc promoters, NQO1, GCLC and TXNRD1 abundance, glutathione status, F₂-isoprostanes, mitochondrial respiration, ATP and Y-maze performance were assessed. Cadmium suppressed NRF2 promoter binding and target proteins, shifted glutathione towards oxidation, increased F₂-isoprostanes, impaired mitochondrial respiration, depleted ATP and reduced spontaneous alternation. DMF improved all these outcomes without significantly lowering hippocampal cadmium (3.85 ± 0.24 versus 3.62 ± 0.22 µg/g; adjusted P = 0.975). Adding ML385 to cadmium plus DMF reduced NRF2 occupancy at the Nqo1 promoter from 1.28 ± 0.09 to 0.62 ± 0.05% input and lowered the GSH/GSSG ratio from 12.26 ± 1.76 to 5.46 ± 0.56. It also reduced oxidative phosphorylation from 56 ± 3 to 40 ± 2.5 pmol O₂/s/mg and spontaneous alternation from 61 ± 2.5% to 48 ± 2.4% (all adjusted P ≤ 0.003), without a significant difference in total arm entries. Several outcomes nevertheless remained partly improved. These findings support a major, although not exclusive, contribution of NRF2 signalling to DMF-mediated redox, mitochondrial and cognitive protection during cadmium exposure in rats.
- 15 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessML385 inhibition of NRF2 partially attenuates dimethyl fumarate-mediated redox and mitochondrial protection in cadmium neurotoxicity
Cadmium disrupts neuronal redox control and mitochondrial energy production, but whether dimethyl fumarate (DMF) protects the brain mainly through NRF2 remains uncertain. Adult male Wistar rats were assigned to control, cadmium, DMF, ML385, cadmium plus DMF, cadmium plus ML385, or cadmium plus DMF plus ML385 groups (n = 12/group). Cadmium chloride (5 mg/kg) and DMF (25 mg/kg) were administered orally, while ML385 (30 mg/kg) was given intraperitoneally, daily for 30 days. Brain cadmium, NRF2 binding to antioxidant response elements in the Nqo1 and Gclc promoters, NQO1, GCLC and TXNRD1 abundance, glutathione status, F₂-isoprostanes, mitochondrial respiration, ATP and Y-maze performance were assessed. Cadmium suppressed NRF2 promoter binding and target proteins, shifted glutathione towards oxidation, increased F₂-isoprostanes, impaired mitochondrial respiration, depleted ATP and reduced spontaneous alternation. DMF improved all these outcomes without significantly lowering hippocampal cadmium (3.85 ± 0.24 versus 3.62 ± 0.22 µg/g; adjusted P = 0.975). Adding ML385 to cadmium plus DMF reduced NRF2 occupancy at the Nqo1 promoter from 1.28 ± 0.09 to 0.62 ± 0.05% input and lowered the GSH/GSSG ratio from 12.26 ± 1.76 to 5.46 ± 0.56. It also reduced oxidative phosphorylation from 56 ± 3 to 40 ± 2.5 pmol O₂/s/mg and spontaneous alternation from 61 ± 2.5% to 48 ± 2.4% (all adjusted P ≤ 0.003), without a significant difference in total arm entries. Several outcomes nevertheless remained partly improved. These findings support a major, although not exclusive, contribution of NRF2 signalling to DMF-mediated redox, mitochondrial and cognitive protection during cadmium exposure in rats.